Updated:
Tengyuan Capital
Tengyuan Capital is an investment fund focused on health care, pharmaceuticals, and other large health sectors. It has made two investments, including a Seed...
Tengyuan Capital
Tengyuan Capital is an investment fund focused on health care, pharmaceuticals, and other large health sectors. It has made two investments, including a Seed VC in Affinity on July 16, 2019. The fund has one portfolio exit, TYK Medicines, which occurred on August 20, 2024.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
Who runs investment decisions at Tengyuan Capital?
No principals are publicly named, and the firm does not maintain a website or LinkedIn presence. Decision-making authority cannot be independently verified without direct access to the firm.
What is Tengyuan Capital's known AUM or deployment scale?
Tengyuan Capital has not publicly disclosed assets under management or cumulative deployment. The firm operates without the institutional disclosures typical of branded Chinese VC platforms, making external sizing impossible.
How does Tengyuan Capital source its deal flow?
There is no public information on Tengyuan's sourcing model. Given its lack of digital presence and institutional brand-building, deal flow likely depends on the personal networks of its unnamed principals — a common pattern among smaller, unlisted Shanghai-based PE vehicles.
Is Tengyuan Capital accessible to external limited partners?
There is no evidence of external LP fundraising. The firm's opaque structure — no website, no LinkedIn, no disclosed team — suggests it may operate as a private investment vehicle rather than a fund actively soliciting institutional commitments.
What investment stages does Tengyuan Capital target?
Per Altss research, Tengyuan's strategy covers early-stage investments, including seed, start-up, and general venture rounds. No specific stage concentration or check-size range has been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: